Quick Answer
Pelthos Therapeutics Inc. reported Stockholders Equity of $38.88 million for the year ending 2025.
- Pelthos Therapeutics Inc. showed an increase of +1,532.6% in Stockholders Equity from 2024 to 2025.
- This data is from Pelthos Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$4.44 million | Q2 2023: -$4.90 million | Q3 2023: -$5.90 million | Q1 2024: $1.13 million | Q2 2024: -$184.0 thousand | Q3 2024: -$1.43 million | Q1 2025: -$4.20 million | Q2 2025: -$6.49 million | Q3 2025: $58.25 million.
- Over the full 5 years of available data (2021 to 2025), Pelthos Therapeutics Inc.'s Stockholders Equity has grown by 1,156.5%.
- Historical annual values: Fiscal year 2025: $38.88 million | Fiscal year 2024: -$2.71 million | Fiscal year 2023: -$6.45 million | Fiscal year 2022: -$3.71 million | Fiscal year 2021: -$3.68 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: